These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 28422274)

  • 21. Polymyositis and chronic graft-versus-host disease: efficacy of intravenous gammaglobulin and methotrexate.
    Blanche P; Dreyfus F; Sicard D
    Clin Exp Rheumatol; 1995; 13(3):377-9. PubMed ID: 7554569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Pediatric Case of Sclerodermatous Graft-Versus-Host Disease Responsive to Ultraviolet A1 Phototherapy.
    Lazzeri L; Tripo L; Pescitelli L; Ricceri F; Prignano F
    Pediatr Dermatol; 2016; 33(2):e99-102. PubMed ID: 26871550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FTY720 ameliorates murine sclerodermatous chronic graft-versus-host disease by promoting expansion of splenic regulatory cells and inhibiting immune cell infiltration into skin.
    Huu DL; Matsushita T; Jin G; Hamaguchi Y; Hasegawa M; Takehara K; Fujimoto M
    Arthritis Rheum; 2013 Jun; 65(6):1624-35. PubMed ID: 23508350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide.
    Zhao JY; Liu SN; Xu LP; Zhang XH; Wang Y; Chen YH; Liu KY; Huang XJ; Mo XD
    Ann Hematol; 2021 Jan; 100(1):169-180. PubMed ID: 33159239
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PUVA treatment in sclerodermatoid spectrum of dermatologic diseases: our initial experience.
    Baum S; Pavlotsky F; Shpiro D; Trau H
    Isr Med Assoc J; 2004 Sep; 6(9):563-4. PubMed ID: 15373320
    [No Abstract]   [Full Text] [Related]  

  • 26. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.
    Zeiser R; von Bubnoff N; Butler J; Mohty M; Niederwieser D; Or R; Szer J; Wagner EM; Zuckerman T; Mahuzier B; Xu J; Wilke C; Gandhi KK; Socié G;
    N Engl J Med; 2020 May; 382(19):1800-1810. PubMed ID: 32320566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.
    Zeiser R; Burchert A; Lengerke C; Verbeek M; Maas-Bauer K; Metzelder SK; Spoerl S; Ditschkowski M; Ecsedi M; Sockel K; Ayuk F; Ajib S; de Fontbrune FS; Na IK; Penter L; Holtick U; Wolf D; Schuler E; Meyer E; Apostolova P; Bertz H; Marks R; Lübbert M; Wäsch R; Scheid C; Stölzel F; Ordemann R; Bug G; Kobbe G; Negrin R; Brune M; Spyridonidis A; Schmitt-Gräff A; van der Velden W; Huls G; Mielke S; Grigoleit GU; Kuball J; Flynn R; Ihorst G; Du J; Blazar BR; Arnold R; Kröger N; Passweg J; Halter J; Socié G; Beelen D; Peschel C; Neubauer A; Finke J; Duyster J; von Bubnoff N
    Leukemia; 2015 Oct; 29(10):2062-8. PubMed ID: 26228813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease.
    Khoury HJ; Langston AA; Kota VK; Wilkinson JA; Pusic I; Jillella A; Bauer S; Kim AS; Roberts D; Al-Kadhimi Z; Bodo I; Winton E; Arellano M; DiPersio JF
    Bone Marrow Transplant; 2018 Jul; 53(7):826-831. PubMed ID: 29367708
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PUVA-bath photochemotherapy and isotretinoin in sclerodermatous graft-versus-host disease.
    Ghoreschi K; Thomas P; Penovici M; Ullmann J; Sander CA; Ledderose G; Plewig G; Kolb HJ; Röcken M
    Eur J Dermatol; 2008; 18(6):667-70. PubMed ID: 18955201
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ruxolitinib for steroid-refractory acute graft-versus-host disease.
    Toama W; Fiala M; Pusic I; Westervelt P; Dipersio JF; Schroeder M
    Transpl Int; 2020 Feb; 33(2):244-246. PubMed ID: 31755139
    [No Abstract]   [Full Text] [Related]  

  • 31. Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: Clinical and immunological results.
    González Vicent M; Molina B; González de Pablo J; Castillo A; Díaz MÁ
    Am J Hematol; 2019 Mar; 94(3):319-326. PubMed ID: 30536806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and feasibility of ruxolitinib in chronic steroid-refractory GVHD in a pediatric intestine transplant.
    Ghobrial S; Gonzalez C; Yazigi N; Kaufman S; Matsumoto C; Fishbein T; Hawksworth J; Kroemer A; Khan K
    Pediatr Transplant; 2021 May; 25(3):e13836. PubMed ID: 32981124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tocilizumab as a potential therapeutic option for children with severe, refractory juvenile localized scleroderma.
    Lythgoe H; Baildam E; Beresford MW; Cleary G; McCann LJ; Pain CE
    Rheumatology (Oxford); 2018 Feb; 57(2):398-401. PubMed ID: 29077971
    [No Abstract]   [Full Text] [Related]  

  • 34. Successful treatment of refractory joint contractures caused by sclerodermatous graft versus host disease.
    Kim JB; Liakopoulou E; Watson JS
    J Plast Reconstr Aesthet Surg; 2008 Oct; 61(10):1235-8. PubMed ID: 17509955
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ruxolitinib as a promising treatment for corticosteroid-refractory graft-versus-host disease.
    Assouan D; Lebon D; Charbonnier A; Royer B; Marolleau JP; Gruson B
    Br J Haematol; 2018 Jun; 181(5):687-689. PubMed ID: 28444730
    [No Abstract]   [Full Text] [Related]  

  • 36. A call for more dermatologic input into chronic graft-vs-host disease clinical trials.
    Cowen EW
    Arch Dermatol; 2009 Mar; 145(3):337-8. PubMed ID: 19289778
    [No Abstract]   [Full Text] [Related]  

  • 37. Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation.
    Abedin S; McKenna E; Chhabra S; Pasquini M; Shah NN; Jerkins J; Baim A; Runaas L; Longo W; Drobyski W; Hari PN; Hamadani M
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1689-1694. PubMed ID: 30965140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Hematopoietic Stem Cell Transplant Patients.
    Khandelwal P; Teusink-Cross A; Davies SM; Nelson AS; Dandoy CE; El-Bietar J; Marsh RA; Kumar AR; Grimley MS; Jodele S; Myers KC
    Biol Blood Marrow Transplant; 2017 Jul; 23(7):1122-1127. PubMed ID: 28344057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation.
    Wu H; Shi J; Luo Y; Tan Y; Zhang M; Lai X; Yu J; Liu L; Fu H; Huang H; Zhao Y
    JAMA Netw Open; 2021 Jan; 4(1):e2034750. PubMed ID: 33502484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ruxolitinib salvage therapy is effective for steroid-refractory graft-versus-host disease in children: A single-center experience.
    Uygun V; Karasu G; Daloğlu H; Öztürkmen S; Kılıç SÇ; Yalçın K; Çelen SS; Hazar V; Yeşilipek A
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28190. PubMed ID: 31981413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.